Conclusion
In conclusion, mirabegron monotherapy improved the JJ stent-related urinary symptoms, body pain, work performance, sexual matters, additional problems, and general health scores. Further studies are needed to clarify the role and mechanisms of mirabegron in the management of SRS.
Competing interests: The authors declare that they have no competing interests.
Endnotes: None
Acknowledgment: None
Funding source: Authors declare they did not receive any funding or support for the present study.